サンプル依頼リスト カート
  • English
  • Korean
市場調査レポート
商品コード
1292519

経口抗ウイルス薬の世界市場規模、シェア、産業動向分析レポート適応症別（ヒト免疫不全ウイルス（HIV）、肝炎、インフルエンザ）、薬剤クラス別、流通チャネル別、地域別展望と予測、2023～2029年

Global Oral Antiviral Market Size, Share & Industry Trends Analysis Report By Indication (Human Immunodeficiency Virus (HIV), Hepatitis, Influenza), By Drug Class, By Distribution Channel, By Regional Outlook and Forecast, 2023 - 2029
出版日: | 発行: KBV Research | ページ情報: 英文 215 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
経口抗ウイルス薬の世界市場規模、シェア、産業動向分析レポート適応症別（ヒト免疫不全ウイルス（HIV）、肝炎、インフルエンザ）、薬剤クラス別、流通チャネル別、地域別展望と予測、2023～2029年
出版日: 2023年05月31日
発行: KBV Research
ページ情報: 英文 215 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

経口抗ウイルス薬市場規模は、予測期間中にCAGR2.3％で成長し、2029年には412億米ドルに達すると予測されます。

しかし、標的を絞った安全で効果的な抗ウイルス薬を最初から作るには時間がかかり、これが市場収益の伸びを抑制すると予想されています。今後のウイルスパンデミックでは、効果的なワクチン接種が開発されている間、ウイルスの拡散を阻止するために、直接作用型抗ウイルス薬のような幅広い抗ウイルス薬が迅速かつ広範囲に展開される必要性が強調されています。

適応症の展望

適応症に基づき、市場は肝炎、ヒト免疫不全ウイルス（HIV）、インフルエンザ、その他に区分されます。2022年の市場では、ヒト免疫不全ウイルス（HIV）分野が最も高い収益シェアを占めています。HIV感染症の発症率の高さ、ブランド薬の入手可能性、治療率の高さ、治療率向上のための政府の試みなどから、平均よりも市場の成長が予測されています。

薬物クラスの展望

薬剤クラス別に見ると、市場はプロテアーゼ阻害剤、逆転写酵素阻害剤、その他に分類されます。2022年の市場では、プロテアーゼ阻害剤分野が大きな収益シェアを獲得しています。プロテアーゼ阻害剤は、タンパク質を切断する酵素を妨害することで機能する薬剤です。最もよく知られているのは、HIV/AIDS、C型肝炎、COVID-19の治療に頻繁に使用される抗ウイルス薬です。プロテアーゼ阻害剤は、HIVや肝炎の治療に広く使用されており、この分野の市場拡大を牽引しています。

流通チャネル別の展望

流通チャネル別では、病院薬局、ドラッグストア・小売薬局、オンラインプロバイダーに二分されます。オンラインプロバイダー分野は、2022年の市場において顕著な収益シェアを記録しました。これは、オンライン薬局が一般住民にますます好まれているためです。また、割引や費用対効果の高いソリューションも提供されています。このセグメントの収益成長は、オンラインサービスへのアクセスが容易になり、インターネットユーザーが急速に増加したことも寄与しています。他の販売店や実店舗と比較して安価な価格設定のため、ほとんどの人がオンラインでの購入を好んでいます。

地域別の展望

地域別では、北米、欧州、アジア太平洋、LAMEAで分析されています。2022年、北米地域は最大の収益シェアを獲得し、市場をリードしました。ヒト免疫不全ウイルス（HIV）やC型肝炎を含むウイルス性疾患の有病率の上昇、経口抗ウイルス薬の主要メーカーの存在、医療インフラの改善などが市場成長に寄与しています。

目次

第1章 市場範囲と調査手法

  • 市場の定義
  • 目的
  • 市場範囲
  • セグメンテーション
  • 調査手法

第2章 市場概要

  • イントロダクション
    • 概要
      • 市場構成とシナリオ
  • 市場に影響を与える主な要因
    • 市場促進要因
    • 市場抑制要因

第3章 世界の経口抗ウイルス薬市場：適応症別

  • 世界のヒト免疫不全ウイルス（HIV）市場：地域別
  • 世界の肝炎市場：地域別
  • 世界のインフルエンザ市場：地域別
  • 世界のその他の市場：地域別

第4章 世界の経口抗ウイルス薬市場：薬物クラス別

  • 世界の逆転写酵素阻害剤市場：地域別
  • 世界のプロテアーゼ阻害剤市場：地域別
  • 世界のその他の市場：地域別

第5章 世界の経口抗ウイルス薬市場：流通チャネル別

  • 世界のドラッグストアおよび小売薬局市場：地域別
  • 世界の病院薬局市場：地域別
  • 世界のオンラインプロバイダー市場：地域別

第6章 世界の経口抗ウイルス薬市場：地域別

  • 北米
    • 北米の市場：国別
      • 米国
      • カナダ
      • メキシコ
      • その他北米地域
  • 欧州
    • 欧州の市場：国別
      • ドイツ
      • 英国
      • フランス
      • ロシア
      • スペイン
      • イタリア
      • その他欧州地域
  • アジア太平洋
    • アジア太平洋の市場：国別
      • 中国
      • 日本
      • インド
      • 韓国
      • シンガポール
      • マレーシア
      • その他アジア太平洋地域
  • ラテンアメリカ・中東・アフリカ
    • ラテンアメリカ・中東・アフリカの市場：国別
      • ブラジル
      • アルゼンチン
      • アラブ首長国連邦
      • サウジアラビア
      • 南アフリカ
      • ナイジェリア
      • その他ラテンアメリカ・中東・アフリカ地域

第7章 企業プロファイル

  • Johnson & Johnson
  • F Hoffmann-La Roche Ltd.
  • Merck & Co, Inc.
  • Bristol Myers Squibb Company
  • Gilead Sciences, Inc
  • Viatris, Inc（Mylan N.V.）
  • AbbVie, Inc
  • GlaxoSmithKline PLC（GSK）
  • Teva Pharmaceutical Industries Ltd
  • Amneal Pharmaceuticals, Inc
図表

LIST OF TABLES

  • TABLE 1 Global Oral Antiviral Market, 2019 - 2022, USD Million
  • TABLE 2 Global Oral Antiviral Market, 2023 - 2029, USD Million
  • TABLE 3 Global Oral Antiviral Market by Indication, 2019 - 2022, USD Million
  • TABLE 4 Global Oral Antiviral Market by Indication, 2023 - 2029, USD Million
  • TABLE 5 Global Human Immunodeficiency Virus (HIV) Market by Region, 2019 - 2022, USD Million
  • TABLE 6 Global Human Immunodeficiency Virus (HIV) Market by Region, 2023 - 2029, USD Million
  • TABLE 7 Global Hepatitis Market by Region, 2019 - 2022, USD Million
  • TABLE 8 Global Hepatitis Market by Region, 2023 - 2029, USD Million
  • TABLE 9 Global Influenza Market by Region, 2019 - 2022, USD Million
  • TABLE 10 Global Influenza Market by Region, 2023 - 2029, USD Million
  • TABLE 11 Global Others Market by Region, 2019 - 2022, USD Million
  • TABLE 12 Global Others Market by Region, 2023 - 2029, USD Million
  • TABLE 13 Global Oral Antiviral Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 14 Global Oral Antiviral Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 15 Global Reverse Transcriptase Inhibitors Market by Region, 2019 - 2022, USD Million
  • TABLE 16 Global Reverse Transcriptase Inhibitors Market by Region, 2023 - 2029, USD Million
  • TABLE 17 Global Protease Inhibitors Market by Region, 2019 - 2022, USD Million
  • TABLE 18 Global Protease Inhibitors Market by Region, 2023 - 2029, USD Million
  • TABLE 19 Global Others Market by Region, 2019 - 2022, USD Million
  • TABLE 20 Global Others Market by Region, 2023 - 2029, USD Million
  • TABLE 21 Global Oral Antiviral Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 22 Global Oral Antiviral Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 23 Global Drug Store & Retail Pharmacies Market by Region, 2019 - 2022, USD Million
  • TABLE 24 Global Drug Store & Retail Pharmacies Market by Region, 2023 - 2029, USD Million
  • TABLE 25 Global Hospital Pharmacies Market by Region, 2019 - 2022, USD Million
  • TABLE 26 Global Hospital Pharmacies Market by Region, 2023 - 2029, USD Million
  • TABLE 27 Global Online Providers Market by Region, 2019 - 2022, USD Million
  • TABLE 28 Global Online Providers Market by Region, 2023 - 2029, USD Million
  • TABLE 29 Global Oral Antiviral Market by Region, 2019 - 2022, USD Million
  • TABLE 30 Global Oral Antiviral Market by Region, 2023 - 2029, USD Million
  • TABLE 31 North America Oral Antiviral Market, 2019 - 2022, USD Million
  • TABLE 32 North America Oral Antiviral Market, 2023 - 2029, USD Million
  • TABLE 33 North America Oral Antiviral Market by Indication, 2019 - 2022, USD Million
  • TABLE 34 North America Oral Antiviral Market by Indication, 2023 - 2029, USD Million
  • TABLE 35 North America Human Immunodeficiency Virus (HIV) Market by Country, 2019 - 2022, USD Million
  • TABLE 36 North America Human Immunodeficiency Virus (HIV) Market by Country, 2023 - 2029, USD Million
  • TABLE 37 North America Hepatitis Market by Country, 2019 - 2022, USD Million
  • TABLE 38 North America Hepatitis Market by Country, 2023 - 2029, USD Million
  • TABLE 39 North America Influenza Market by Country, 2019 - 2022, USD Million
  • TABLE 40 North America Influenza Market by Country, 2023 - 2029, USD Million
  • TABLE 41 North America Others Market by Country, 2019 - 2022, USD Million
  • TABLE 42 North America Others Market by Country, 2023 - 2029, USD Million
  • TABLE 43 North America Oral Antiviral Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 44 North America Oral Antiviral Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 45 North America Reverse Transcriptase Inhibitors Market by Country, 2019 - 2022, USD Million
  • TABLE 46 North America Reverse Transcriptase Inhibitors Market by Country, 2023 - 2029, USD Million
  • TABLE 47 North America Protease Inhibitors Market by Country, 2019 - 2022, USD Million
  • TABLE 48 North America Protease Inhibitors Market by Country, 2023 - 2029, USD Million
  • TABLE 49 North America Others Market by Country, 2019 - 2022, USD Million
  • TABLE 50 North America Others Market by Country, 2023 - 2029, USD Million
  • TABLE 51 North America Oral Antiviral Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 52 North America Oral Antiviral Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 53 North America Drug Store & Retail Pharmacies Market by Country, 2019 - 2022, USD Million
  • TABLE 54 North America Drug Store & Retail Pharmacies Market by Country, 2023 - 2029, USD Million
  • TABLE 55 North America Hospital Pharmacies Market by Country, 2019 - 2022, USD Million
  • TABLE 56 North America Hospital Pharmacies Market by Country, 2023 - 2029, USD Million
  • TABLE 57 North America Online Providers Market by Country, 2019 - 2022, USD Million
  • TABLE 58 North America Online Providers Market by Country, 2023 - 2029, USD Million
  • TABLE 59 North America Oral Antiviral Market by Country, 2019 - 2022, USD Million
  • TABLE 60 North America Oral Antiviral Market by Country, 2023 - 2029, USD Million
  • TABLE 61 US Oral Antiviral Market, 2019 - 2022, USD Million
  • TABLE 62 US Oral Antiviral Market, 2023 - 2029, USD Million
  • TABLE 63 US Oral Antiviral Market by Indication, 2019 - 2022, USD Million
  • TABLE 64 US Oral Antiviral Market by Indication, 2023 - 2029, USD Million
  • TABLE 65 US Oral Antiviral Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 66 US Oral Antiviral Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 67 US Oral Antiviral Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 68 US Oral Antiviral Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 69 Canada Oral Antiviral Market, 2019 - 2022, USD Million
  • TABLE 70 Canada Oral Antiviral Market, 2023 - 2029, USD Million
  • TABLE 71 Canada Oral Antiviral Market by Indication, 2019 - 2022, USD Million
  • TABLE 72 Canada Oral Antiviral Market by Indication, 2023 - 2029, USD Million
  • TABLE 73 Canada Oral Antiviral Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 74 Canada Oral Antiviral Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 75 Canada Oral Antiviral Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 76 Canada Oral Antiviral Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 77 Mexico Oral Antiviral Market, 2019 - 2022, USD Million
  • TABLE 78 Mexico Oral Antiviral Market, 2023 - 2029, USD Million
  • TABLE 79 Mexico Oral Antiviral Market by Indication, 2019 - 2022, USD Million
  • TABLE 80 Mexico Oral Antiviral Market by Indication, 2023 - 2029, USD Million
  • TABLE 81 Mexico Oral Antiviral Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 82 Mexico Oral Antiviral Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 83 Mexico Oral Antiviral Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 84 Mexico Oral Antiviral Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 85 Rest of North America Oral Antiviral Market, 2019 - 2022, USD Million
  • TABLE 86 Rest of North America Oral Antiviral Market, 2023 - 2029, USD Million
  • TABLE 87 Rest of North America Oral Antiviral Market by Indication, 2019 - 2022, USD Million
  • TABLE 88 Rest of North America Oral Antiviral Market by Indication, 2023 - 2029, USD Million
  • TABLE 89 Rest of North America Oral Antiviral Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 90 Rest of North America Oral Antiviral Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 91 Rest of North America Oral Antiviral Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 92 Rest of North America Oral Antiviral Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 93 Europe Oral Antiviral Market, 2019 - 2022, USD Million
  • TABLE 94 Europe Oral Antiviral Market, 2023 - 2029, USD Million
  • TABLE 95 Europe Oral Antiviral Market by Indication, 2019 - 2022, USD Million
  • TABLE 96 Europe Oral Antiviral Market by Indication, 2023 - 2029, USD Million
  • TABLE 97 Europe Human Immunodeficiency Virus (HIV) Market by Country, 2019 - 2022, USD Million
  • TABLE 98 Europe Human Immunodeficiency Virus (HIV) Market by Country, 2023 - 2029, USD Million
  • TABLE 99 Europe Hepatitis Market by Country, 2019 - 2022, USD Million
  • TABLE 100 Europe Hepatitis Market by Country, 2023 - 2029, USD Million
  • TABLE 101 Europe Influenza Market by Country, 2019 - 2022, USD Million
  • TABLE 102 Europe Influenza Market by Country, 2023 - 2029, USD Million
  • TABLE 103 Europe Others Market by Country, 2019 - 2022, USD Million
  • TABLE 104 Europe Others Market by Country, 2023 - 2029, USD Million
  • TABLE 105 Europe Oral Antiviral Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 106 Europe Oral Antiviral Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 107 Europe Reverse Transcriptase Inhibitors Market by Country, 2019 - 2022, USD Million
  • TABLE 108 Europe Reverse Transcriptase Inhibitors Market by Country, 2023 - 2029, USD Million
  • TABLE 109 Europe Protease Inhibitors Market by Country, 2019 - 2022, USD Million
  • TABLE 110 Europe Protease Inhibitors Market by Country, 2023 - 2029, USD Million
  • TABLE 111 Europe Others Market by Country, 2019 - 2022, USD Million
  • TABLE 112 Europe Others Market by Country, 2023 - 2029, USD Million
  • TABLE 113 Europe Oral Antiviral Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 114 Europe Oral Antiviral Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 115 Europe Drug Store & Retail Pharmacies Market by Country, 2019 - 2022, USD Million
  • TABLE 116 Europe Drug Store & Retail Pharmacies Market by Country, 2023 - 2029, USD Million
  • TABLE 117 Europe Hospital Pharmacies Market by Country, 2019 - 2022, USD Million
  • TABLE 118 Europe Hospital Pharmacies Market by Country, 2023 - 2029, USD Million
  • TABLE 119 Europe Online Providers Market by Country, 2019 - 2022, USD Million
  • TABLE 120 Europe Online Providers Market by Country, 2023 - 2029, USD Million
  • TABLE 121 Europe Oral Antiviral Market by Country, 2019 - 2022, USD Million
  • TABLE 122 Europe Oral Antiviral Market by Country, 2023 - 2029, USD Million
  • TABLE 123 Germany Oral Antiviral Market, 2019 - 2022, USD Million
  • TABLE 124 Germany Oral Antiviral Market, 2023 - 2029, USD Million
  • TABLE 125 Germany Oral Antiviral Market by Indication, 2019 - 2022, USD Million
  • TABLE 126 Germany Oral Antiviral Market by Indication, 2023 - 2029, USD Million
  • TABLE 127 Germany Oral Antiviral Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 128 Germany Oral Antiviral Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 129 Germany Oral Antiviral Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 130 Germany Oral Antiviral Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 131 UK Oral Antiviral Market, 2019 - 2022, USD Million
  • TABLE 132 UK Oral Antiviral Market, 2023 - 2029, USD Million
  • TABLE 133 UK Oral Antiviral Market by Indication, 2019 - 2022, USD Million
  • TABLE 134 UK Oral Antiviral Market by Indication, 2023 - 2029, USD Million
  • TABLE 135 UK Oral Antiviral Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 136 UK Oral Antiviral Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 137 UK Oral Antiviral Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 138 UK Oral Antiviral Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 139 France Oral Antiviral Market, 2019 - 2022, USD Million
  • TABLE 140 France Oral Antiviral Market, 2023 - 2029, USD Million
  • TABLE 141 France Oral Antiviral Market by Indication, 2019 - 2022, USD Million
  • TABLE 142 France Oral Antiviral Market by Indication, 2023 - 2029, USD Million
  • TABLE 143 France Oral Antiviral Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 144 France Oral Antiviral Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 145 France Oral Antiviral Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 146 France Oral Antiviral Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 147 Russia Oral Antiviral Market, 2019 - 2022, USD Million
  • TABLE 148 Russia Oral Antiviral Market, 2023 - 2029, USD Million
  • TABLE 149 Russia Oral Antiviral Market by Indication, 2019 - 2022, USD Million
  • TABLE 150 Russia Oral Antiviral Market by Indication, 2023 - 2029, USD Million
  • TABLE 151 Russia Oral Antiviral Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 152 Russia Oral Antiviral Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 153 Russia Oral Antiviral Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 154 Russia Oral Antiviral Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 155 Spain Oral Antiviral Market, 2019 - 2022, USD Million
  • TABLE 156 Spain Oral Antiviral Market, 2023 - 2029, USD Million
  • TABLE 157 Spain Oral Antiviral Market by Indication, 2019 - 2022, USD Million
  • TABLE 158 Spain Oral Antiviral Market by Indication, 2023 - 2029, USD Million
  • TABLE 159 Spain Oral Antiviral Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 160 Spain Oral Antiviral Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 161 Spain Oral Antiviral Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 162 Spain Oral Antiviral Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 163 Italy Oral Antiviral Market, 2019 - 2022, USD Million
  • TABLE 164 Italy Oral Antiviral Market, 2023 - 2029, USD Million
  • TABLE 165 Italy Oral Antiviral Market by Indication, 2019 - 2022, USD Million
  • TABLE 166 Italy Oral Antiviral Market by Indication, 2023 - 2029, USD Million
  • TABLE 167 Italy Oral Antiviral Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 168 Italy Oral Antiviral Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 169 Italy Oral Antiviral Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 170 Italy Oral Antiviral Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 171 Rest of Europe Oral Antiviral Market, 2019 - 2022, USD Million
  • TABLE 172 Rest of Europe Oral Antiviral Market, 2023 - 2029, USD Million
  • TABLE 173 Rest of Europe Oral Antiviral Market by Indication, 2019 - 2022, USD Million
  • TABLE 174 Rest of Europe Oral Antiviral Market by Indication, 2023 - 2029, USD Million
  • TABLE 175 Rest of Europe Oral Antiviral Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 176 Rest of Europe Oral Antiviral Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 177 Rest of Europe Oral Antiviral Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 178 Rest of Europe Oral Antiviral Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 179 Asia Pacific Oral Antiviral Market, 2019 - 2022, USD Million
  • TABLE 180 Asia Pacific Oral Antiviral Market, 2023 - 2029, USD Million
  • TABLE 181 Asia Pacific Oral Antiviral Market by Indication, 2019 - 2022, USD Million
  • TABLE 182 Asia Pacific Oral Antiviral Market by Indication, 2023 - 2029, USD Million
  • TABLE 183 Asia Pacific Human Immunodeficiency Virus (HIV) Market by Country, 2019 - 2022, USD Million
  • TABLE 184 Asia Pacific Human Immunodeficiency Virus (HIV) Market by Country, 2023 - 2029, USD Million
  • TABLE 185 Asia Pacific Hepatitis Market by Country, 2019 - 2022, USD Million
  • TABLE 186 Asia Pacific Hepatitis Market by Country, 2023 - 2029, USD Million
  • TABLE 187 Asia Pacific Influenza Market by Country, 2019 - 2022, USD Million
  • TABLE 188 Asia Pacific Influenza Market by Country, 2023 - 2029, USD Million
  • TABLE 189 Asia Pacific Others Market by Country, 2019 - 2022, USD Million
  • TABLE 190 Asia Pacific Others Market by Country, 2023 - 2029, USD Million
  • TABLE 191 Asia Pacific Oral Antiviral Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 192 Asia Pacific Oral Antiviral Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 193 Asia Pacific Reverse Transcriptase Inhibitors Market by Country, 2019 - 2022, USD Million
  • TABLE 194 Asia Pacific Reverse Transcriptase Inhibitors Market by Country, 2023 - 2029, USD Million
  • TABLE 195 Asia Pacific Protease Inhibitors Market by Country, 2019 - 2022, USD Million
  • TABLE 196 Asia Pacific Protease Inhibitors Market by Country, 2023 - 2029, USD Million
  • TABLE 197 Asia Pacific Others Market by Country, 2019 - 2022, USD Million
  • TABLE 198 Asia Pacific Others Market by Country, 2023 - 2029, USD Million
  • TABLE 199 Asia Pacific Oral Antiviral Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 200 Asia Pacific Oral Antiviral Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 201 Asia Pacific Drug Store & Retail Pharmacies Market by Country, 2019 - 2022, USD Million
  • TABLE 202 Asia Pacific Drug Store & Retail Pharmacies Market by Country, 2023 - 2029, USD Million
  • TABLE 203 Asia Pacific Hospital Pharmacies Market by Country, 2019 - 2022, USD Million
  • TABLE 204 Asia Pacific Hospital Pharmacies Market by Country, 2023 - 2029, USD Million
  • TABLE 205 Asia Pacific Online Providers Market by Country, 2019 - 2022, USD Million
  • TABLE 206 Asia Pacific Online Providers Market by Country, 2023 - 2029, USD Million
  • TABLE 207 Asia Pacific Oral Antiviral Market by Country, 2019 - 2022, USD Million
  • TABLE 208 Asia Pacific Oral Antiviral Market by Country, 2023 - 2029, USD Million
  • TABLE 209 China Oral Antiviral Market, 2019 - 2022, USD Million
  • TABLE 210 China Oral Antiviral Market, 2023 - 2029, USD Million
  • TABLE 211 China Oral Antiviral Market by Indication, 2019 - 2022, USD Million
  • TABLE 212 China Oral Antiviral Market by Indication, 2023 - 2029, USD Million
  • TABLE 213 China Oral Antiviral Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 214 China Oral Antiviral Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 215 China Oral Antiviral Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 216 China Oral Antiviral Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 217 Japan Oral Antiviral Market, 2019 - 2022, USD Million
  • TABLE 218 Japan Oral Antiviral Market, 2023 - 2029, USD Million
  • TABLE 219 Japan Oral Antiviral Market by Indication, 2019 - 2022, USD Million
  • TABLE 220 Japan Oral Antiviral Market by Indication, 2023 - 2029, USD Million
  • TABLE 221 Japan Oral Antiviral Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 222 Japan Oral Antiviral Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 223 Japan Oral Antiviral Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 224 Japan Oral Antiviral Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 225 India Oral Antiviral Market, 2019 - 2022, USD Million
  • TABLE 226 India Oral Antiviral Market, 2023 - 2029, USD Million
  • TABLE 227 India Oral Antiviral Market by Indication, 2019 - 2022, USD Million
  • TABLE 228 India Oral Antiviral Market by Indication, 2023 - 2029, USD Million
  • TABLE 229 India Oral Antiviral Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 230 India Oral Antiviral Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 231 India Oral Antiviral Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 232 India Oral Antiviral Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 233 South Korea Oral Antiviral Market, 2019 - 2022, USD Million
  • TABLE 234 South Korea Oral Antiviral Market, 2023 - 2029, USD Million
  • TABLE 235 South Korea Oral Antiviral Market by Indication, 2019 - 2022, USD Million
  • TABLE 236 South Korea Oral Antiviral Market by Indication, 2023 - 2029, USD Million
  • TABLE 237 South Korea Oral Antiviral Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 238 South Korea Oral Antiviral Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 239 South Korea Oral Antiviral Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 240 South Korea Oral Antiviral Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 241 Singapore Oral Antiviral Market, 2019 - 2022, USD Million
  • TABLE 242 Singapore Oral Antiviral Market, 2023 - 2029, USD Million
  • TABLE 243 Singapore Oral Antiviral Market by Indication, 2019 - 2022, USD Million
  • TABLE 244 Singapore Oral Antiviral Market by Indication, 2023 - 2029, USD Million
  • TABLE 245 Singapore Oral Antiviral Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 246 Singapore Oral Antiviral Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 247 Singapore Oral Antiviral Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 248 Singapore Oral Antiviral Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 249 Malaysia Oral Antiviral Market, 2019 - 2022, USD Million
  • TABLE 250 Malaysia Oral Antiviral Market, 2023 - 2029, USD Million
  • TABLE 251 Malaysia Oral Antiviral Market by Indication, 2019 - 2022, USD Million
  • TABLE 252 Malaysia Oral Antiviral Market by Indication, 2023 - 2029, USD Million
  • TABLE 253 Malaysia Oral Antiviral Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 254 Malaysia Oral Antiviral Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 255 Malaysia Oral Antiviral Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 256 Malaysia Oral Antiviral Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 257 Rest of Asia Pacific Oral Antiviral Market, 2019 - 2022, USD Million
  • TABLE 258 Rest of Asia Pacific Oral Antiviral Market, 2023 - 2029, USD Million
  • TABLE 259 Rest of Asia Pacific Oral Antiviral Market by Indication, 2019 - 2022, USD Million
  • TABLE 260 Rest of Asia Pacific Oral Antiviral Market by Indication, 2023 - 2029, USD Million
  • TABLE 261 Rest of Asia Pacific Oral Antiviral Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 262 Rest of Asia Pacific Oral Antiviral Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 263 Rest of Asia Pacific Oral Antiviral Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 264 Rest of Asia Pacific Oral Antiviral Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 265 LAMEA Oral Antiviral Market, 2019 - 2022, USD Million
  • TABLE 266 LAMEA Oral Antiviral Market, 2023 - 2029, USD Million
  • TABLE 267 LAMEA Oral Antiviral Market by Indication, 2019 - 2022, USD Million
  • TABLE 268 LAMEA Oral Antiviral Market by Indication, 2023 - 2029, USD Million
  • TABLE 269 LAMEA Human Immunodeficiency Virus (HIV) Market by Country, 2019 - 2022, USD Million
  • TABLE 270 LAMEA Human Immunodeficiency Virus (HIV) Market by Country, 2023 - 2029, USD Million
  • TABLE 271 LAMEA Hepatitis Market by Country, 2019 - 2022, USD Million
  • TABLE 272 LAMEA Hepatitis Market by Country, 2023 - 2029, USD Million
  • TABLE 273 LAMEA Influenza Market by Country, 2019 - 2022, USD Million
  • TABLE 274 LAMEA Influenza Market by Country, 2023 - 2029, USD Million
  • TABLE 275 LAMEA Others Market by Country, 2019 - 2022, USD Million
  • TABLE 276 LAMEA Others Market by Country, 2023 - 2029, USD Million
  • TABLE 277 LAMEA Oral Antiviral Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 278 LAMEA Oral Antiviral Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 279 LAMEA Reverse Transcriptase Inhibitors Market by Country, 2019 - 2022, USD Million
  • TABLE 280 LAMEA Reverse Transcriptase Inhibitors Market by Country, 2023 - 2029, USD Million
  • TABLE 281 LAMEA Protease Inhibitors Market by Country, 2019 - 2022, USD Million
  • TABLE 282 LAMEA Protease Inhibitors Market by Country, 2023 - 2029, USD Million
  • TABLE 283 LAMEA Others Market by Country, 2019 - 2022, USD Million
  • TABLE 284 LAMEA Others Market by Country, 2023 - 2029, USD Million
  • TABLE 285 LAMEA Oral Antiviral Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 286 LAMEA Oral Antiviral Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 287 LAMEA Drug Store & Retail Pharmacies Market by Country, 2019 - 2022, USD Million
  • TABLE 288 LAMEA Drug Store & Retail Pharmacies Market by Country, 2023 - 2029, USD Million
  • TABLE 289 LAMEA Hospital Pharmacies Market by Country, 2019 - 2022, USD Million
  • TABLE 290 LAMEA Hospital Pharmacies Market by Country, 2023 - 2029, USD Million
  • TABLE 291 LAMEA Online Providers Market by Country, 2019 - 2022, USD Million
  • TABLE 292 LAMEA Online Providers Market by Country, 2023 - 2029, USD Million
  • TABLE 293 LAMEA Oral Antiviral Market by Country, 2019 - 2022, USD Million
  • TABLE 294 LAMEA Oral Antiviral Market by Country, 2023 - 2029, USD Million
  • TABLE 295 Brazil Oral Antiviral Market, 2019 - 2022, USD Million
  • TABLE 296 Brazil Oral Antiviral Market, 2023 - 2029, USD Million
  • TABLE 297 Brazil Oral Antiviral Market by Indication, 2019 - 2022, USD Million
  • TABLE 298 Brazil Oral Antiviral Market by Indication, 2023 - 2029, USD Million
  • TABLE 299 Brazil Oral Antiviral Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 300 Brazil Oral Antiviral Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 301 Brazil Oral Antiviral Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 302 Brazil Oral Antiviral Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 303 Argentina Oral Antiviral Market, 2019 - 2022, USD Million
  • TABLE 304 Argentina Oral Antiviral Market, 2023 - 2029, USD Million
  • TABLE 305 Argentina Oral Antiviral Market by Indication, 2019 - 2022, USD Million
  • TABLE 306 Argentina Oral Antiviral Market by Indication, 2023 - 2029, USD Million
  • TABLE 307 Argentina Oral Antiviral Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 308 Argentina Oral Antiviral Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 309 Argentina Oral Antiviral Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 310 Argentina Oral Antiviral Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 311 UAE Oral Antiviral Market, 2019 - 2022, USD Million
  • TABLE 312 UAE Oral Antiviral Market, 2023 - 2029, USD Million
  • TABLE 313 UAE Oral Antiviral Market by Indication, 2019 - 2022, USD Million
  • TABLE 314 UAE Oral Antiviral Market by Indication, 2023 - 2029, USD Million
  • TABLE 315 UAE Oral Antiviral Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 316 UAE Oral Antiviral Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 317 UAE Oral Antiviral Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 318 UAE Oral Antiviral Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 319 Saudi Arabia Oral Antiviral Market, 2019 - 2022, USD Million
  • TABLE 320 Saudi Arabia Oral Antiviral Market, 2023 - 2029, USD Million
  • TABLE 321 Saudi Arabia Oral Antiviral Market by Indication, 2019 - 2022, USD Million
  • TABLE 322 Saudi Arabia Oral Antiviral Market by Indication, 2023 - 2029, USD Million
  • TABLE 323 Saudi Arabia Oral Antiviral Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 324 Saudi Arabia Oral Antiviral Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 325 Saudi Arabia Oral Antiviral Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 326 Saudi Arabia Oral Antiviral Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 327 South Africa Oral Antiviral Market, 2019 - 2022, USD Million
  • TABLE 328 South Africa Oral Antiviral Market, 2023 - 2029, USD Million
  • TABLE 329 South Africa Oral Antiviral Market by Indication, 2019 - 2022, USD Million
  • TABLE 330 South Africa Oral Antiviral Market by Indication, 2023 - 2029, USD Million
  • TABLE 331 South Africa Oral Antiviral Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 332 South Africa Oral Antiviral Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 333 South Africa Oral Antiviral Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 334 South Africa Oral Antiviral Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 335 Nigeria Oral Antiviral Market, 2019 - 2022, USD Million
  • TABLE 336 Nigeria Oral Antiviral Market, 2023 - 2029, USD Million
  • TABLE 337 Nigeria Oral Antiviral Market by Indication, 2019 - 2022, USD Million
  • TABLE 338 Nigeria Oral Antiviral Market by Indication, 2023 - 2029, USD Million
  • TABLE 339 Nigeria Oral Antiviral Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 340 Nigeria Oral Antiviral Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 341 Nigeria Oral Antiviral Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 342 Nigeria Oral Antiviral Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 343 Rest of LAMEA Oral Antiviral Market, 2019 - 2022, USD Million
  • TABLE 344 Rest of LAMEA Oral Antiviral Market, 2023 - 2029, USD Million
  • TABLE 345 Rest of LAMEA Oral Antiviral Market by Indication, 2019 - 2022, USD Million
  • TABLE 346 Rest of LAMEA Oral Antiviral Market by Indication, 2023 - 2029, USD Million
  • TABLE 347 Rest of LAMEA Oral Antiviral Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 348 Rest of LAMEA Oral Antiviral Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 349 Rest of LAMEA Oral Antiviral Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 350 Rest of LAMEA Oral Antiviral Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 351 Key information -Johnson & Johnson
  • TABLE 352 KEY INFORMATION - F. Hoffmann-La Roche Ltd.
  • TABLE 353 KEY INFORMATION - Merck & Co., Inc.
  • TABLE 354 Key Information - Bristol Myers Squibb Company
  • TABLE 355 Key Information - Gilead Sciences, Inc.
  • TABLE 356 key information - Viatris, Inc.
  • TABLE 357 Key information - AbbVie, Inc.
  • TABLE 358 Key Information - GlaxoSmithKline PLC
  • TABLE 359 Key Information - Teva Pharmaceuticals Industries Ltd.
  • TABLE 360 Key Information - Amneal Pharmaceuticals, INc.

List of Figures

  • FIG 1 Methodology for the research
  • FIG 2 Global Oral Antiviral Market Share by Indication, 2022
  • FIG 3 Global Oral Antiviral Market Share by Indication, 2029
  • FIG 4 Global Oral Antiviral Market by Indication, 2019 - 2029, USD Million
  • FIG 5 Global Oral Antiviral Market Share by Drug Class, 2022
  • FIG 6 Global Oral Antiviral Market Share by Drug Class, 2029
  • FIG 7 Global Oral Antiviral Market by Drug Class, 2019 - 2029, USD Million
  • FIG 8 Global Oral Antiviral Market Share by Distribution Channel, 2022
  • FIG 9 Global Oral Antiviral Market Share by Distribution Channel, 2029
  • FIG 10 Global Oral Antiviral Market by Distribution Channel, 2019 - 2029, USD Million
  • FIG 11 Global Oral Antiviral Market Share by Region, 2022
  • FIG 12 Global Oral Antiviral Market Share by Region, 2029
  • FIG 13 Global Oral Antiviral Market by Region, 2019 - 2029, USD Million
  • FIG 14 SWOT analysis: Johnson & Johnson
目次

The Global Oral Antiviral Market size is expected to reach $41.2 billion by 2029, rising at a market growth of 2.3% CAGR during the forecast period.

Influenza constitutes a significant share of the market and generated $2,811.5 million revenue in 2022 as children are effective recipients of influenza viruses, and those aged 5 to 9 often have the highest rates of infection and sickness. The worldwide prevalence of influenza and the rising number of drug launches are the main drivers of the expansion of the market. As a result, players are concentrating on research & development with potential candidates to address the substantial unmet demands in the market. Some of the factors impacting the market are growing incidence of viral infection, growing Healthcare expenditures, and limited options of accessible, affordable, and broad-spectrum oral antivirals.

Viral infections are now much more common than they were in the recent past. It depends on a variety of conditions whether new infectious diseases originate, or "old" infectious diseases reemerge. Many diseases are brought on by human behavior and habits; however, some are the consequence of natural processes like the development of pathogens over time. The increasing number & size of investments made within the healthcare industry by governments of different nations is one of the primary drivers of the market's growth. Because of their rapid economic development and rising healthcare expenses, more developing countries are projected to have more access to high-quality healthcare.

However, it takes time to create a targeted, safe, and effective antiviral from the beginning, which is anticipated to restrain market revenue growth. Future viral pandemics highlight the need for broad-spectrum antiviral medications, like direct-acting antivirals, that may be promptly and broadly deployed to stop viral spread while effective vaccinations are being developed.

Indication Outlook

Based on indication, the market is segmented into hepatitis, human immunodeficiency virus (HIV), influenza and others. In 2022, the human immunodeficiency virus (HIV) segment held the highest revenue share in the market. The market is predicted to grow faster than average due to the high incidence of HIV infection, availability of branded medications, high treatment rate, and government attempts to raise the treatment rate.

Drug Class Outlook

On the basis of drug class, the market is fragmented into protease inhibitors, reverse transcriptase inhibitors, and others. The protease inhibitors segment garnered a significant revenue share in the market in 2022. Protease inhibitors are drugs that work by obstructing the protein-cleaving enzymes. Among the most well-known are antiviral medications frequently used to treat HIV/AIDS, hepatitis C, and COVID-19. Protease inhibitors are widely used to treat HIV and hepatitis, driving market expansion in this segment.

Distribution Channel Outlook

By distribution channel, the market is bifurcated into hospital pharmacies, drug store & retail pharmacies, and online providers. The online providers segment recorded a remarkable revenue share in the market in 2022. This is because online pharmacies are becoming more and more well-liked by the general population. They also provide discounts and cost-effective solutions. This segment's revenue growth is also aided by easier access to online services and a quicker increase in Internet users. Due to the cheaper pricing compared to other merchants and physical stores, most people prefer to purchase online.

Regional Outlook

Region wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the North America region led the market by generating the largest revenue share. The rise in the prevalence of viral illnesses including the human immunodeficiency virus (HIV) and hepatitis C, the presence of major manufacturers of oral antivirals, and improvements in healthcare infrastructure all contribute to the market growth.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Bristol Myers Squibb Company, Gilead Sciences, Inc., Viatris, Inc. (Mylan N.V.), AbbVie, Inc., GlaxoSmithKline PLC (GSK), Teva Pharmaceutical Industries Ltd., and Amneal Pharmaceuticals, Inc.

Scope of the Study

Market Segments covered in the Report:

By Indication

  • Human Immunodeficiency Virus (HIV)
  • Hepatitis
  • Influenza
  • Others

By Drug Class

  • Reverse Transcriptase Inhibitors
  • Protease Inhibitors
  • Others

By Distribution Channel

  • Drug Store & Retail Pharmacies
  • Hospital Pharmacies
  • Online Providers

By Geography

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Malaysia
    • Rest of Asia Pacific
  • LAMEA
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA

Companies Profiled

  • Johnson & Johnson
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Bristol Myers Squibb Company
  • Gilead Sciences, Inc.
  • Viatris, Inc. (Mylan N.V.)
  • AbbVie, Inc.
  • GlaxoSmithKline PLC (GSK)
  • Teva Pharmaceutical Industries Ltd.
  • Amneal Pharmaceuticals, Inc.

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 Global Oral Antiviral Market, by Indication
    • 1.4.2 Global Oral Antiviral Market, by Drug Class
    • 1.4.3 Global Oral Antiviral Market, by Distribution Channel
    • 1.4.4 Global Oral Antiviral Market, by Geography
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
      • 2.1.1.1 Market Composition & Scenario
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. Global Oral Antiviral Market by Indication

  • 3.1 Global Human Immunodeficiency Virus (HIV) Market by Region
  • 3.2 Global Hepatitis Market by Region
  • 3.3 Global Influenza Market by Region
  • 3.4 Global Others Market by Region

Chapter 4. Global Oral Antiviral Market by Drug Class

  • 4.1 Global Reverse Transcriptase Inhibitors Market by Region
  • 4.2 Global Protease Inhibitors Market by Region
  • 4.3 Global Others Market by Region

Chapter 5. Global Oral Antiviral Market by Distribution Channel

  • 5.1 Global Drug Store & Retail Pharmacies Market by Region
  • 5.2 Global Hospital Pharmacies Market by Region
  • 5.3 Global Online Providers Market by Region

Chapter 6. Global Oral Antiviral Market by Region

  • 6.1 North America Oral Antiviral Market
    • 6.1.1 North America Oral Antiviral Market by Indication
      • 6.1.1.1 North America Human Immunodeficiency Virus (HIV) Market by Country
      • 6.1.1.2 North America Hepatitis Market by Country
      • 6.1.1.3 North America Influenza Market by Country
      • 6.1.1.4 North America Others Market by Country
    • 6.1.2 North America Oral Antiviral Market by Drug Class
      • 6.1.2.1 North America Reverse Transcriptase Inhibitors Market by Country
      • 6.1.2.2 North America Protease Inhibitors Market by Country
      • 6.1.2.3 North America Others Market by Country
    • 6.1.3 North America Oral Antiviral Market by Distribution Channel
      • 6.1.3.1 North America Drug Store & Retail Pharmacies Market by Country
      • 6.1.3.2 North America Hospital Pharmacies Market by Country
      • 6.1.3.3 North America Online Providers Market by Country
    • 6.1.4 North America Oral Antiviral Market by Country
      • 6.1.4.1 US Oral Antiviral Market
        • 6.1.4.1.1 US Oral Antiviral Market by Indication
        • 6.1.4.1.2 US Oral Antiviral Market by Drug Class
        • 6.1.4.1.3 US Oral Antiviral Market by Distribution Channel
      • 6.1.4.2 Canada Oral Antiviral Market
        • 6.1.4.2.1 Canada Oral Antiviral Market by Indication
        • 6.1.4.2.2 Canada Oral Antiviral Market by Drug Class
        • 6.1.4.2.3 Canada Oral Antiviral Market by Distribution Channel
      • 6.1.4.3 Mexico Oral Antiviral Market
        • 6.1.4.3.1 Mexico Oral Antiviral Market by Indication
        • 6.1.4.3.2 Mexico Oral Antiviral Market by Drug Class
        • 6.1.4.3.3 Mexico Oral Antiviral Market by Distribution Channel
      • 6.1.4.4 Rest of North America Oral Antiviral Market
        • 6.1.4.4.1 Rest of North America Oral Antiviral Market by Indication
        • 6.1.4.4.2 Rest of North America Oral Antiviral Market by Drug Class
        • 6.1.4.4.3 Rest of North America Oral Antiviral Market by Distribution Channel
  • 6.2 Europe Oral Antiviral Market
    • 6.2.1 Europe Oral Antiviral Market by Indication
      • 6.2.1.1 Europe Human Immunodeficiency Virus (HIV) Market by Country
      • 6.2.1.2 Europe Hepatitis Market by Country
      • 6.2.1.3 Europe Influenza Market by Country
      • 6.2.1.4 Europe Others Market by Country
    • 6.2.2 Europe Oral Antiviral Market by Drug Class
      • 6.2.2.1 Europe Reverse Transcriptase Inhibitors Market by Country
      • 6.2.2.2 Europe Protease Inhibitors Market by Country
      • 6.2.2.3 Europe Others Market by Country
    • 6.2.3 Europe Oral Antiviral Market by Distribution Channel
      • 6.2.3.1 Europe Drug Store & Retail Pharmacies Market by Country
      • 6.2.3.2 Europe Hospital Pharmacies Market by Country
      • 6.2.3.3 Europe Online Providers Market by Country
    • 6.2.4 Europe Oral Antiviral Market by Country
      • 6.2.4.1 Germany Oral Antiviral Market
        • 6.2.4.1.1 Germany Oral Antiviral Market by Indication
        • 6.2.4.1.2 Germany Oral Antiviral Market by Drug Class
        • 6.2.4.1.3 Germany Oral Antiviral Market by Distribution Channel
      • 6.2.4.2 UK Oral Antiviral Market
        • 6.2.4.2.1 UK Oral Antiviral Market by Indication
        • 6.2.4.2.2 UK Oral Antiviral Market by Drug Class
        • 6.2.4.2.3 UK Oral Antiviral Market by Distribution Channel
      • 6.2.4.3 France Oral Antiviral Market
        • 6.2.4.3.1 France Oral Antiviral Market by Indication
        • 6.2.4.3.2 France Oral Antiviral Market by Drug Class
        • 6.2.4.3.3 France Oral Antiviral Market by Distribution Channel
      • 6.2.4.4 Russia Oral Antiviral Market
        • 6.2.4.4.1 Russia Oral Antiviral Market by Indication
        • 6.2.4.4.2 Russia Oral Antiviral Market by Drug Class
        • 6.2.4.4.3 Russia Oral Antiviral Market by Distribution Channel
      • 6.2.4.5 Spain Oral Antiviral Market
        • 6.2.4.5.1 Spain Oral Antiviral Market by Indication
        • 6.2.4.5.2 Spain Oral Antiviral Market by Drug Class
        • 6.2.4.5.3 Spain Oral Antiviral Market by Distribution Channel
      • 6.2.4.6 Italy Oral Antiviral Market
        • 6.2.4.6.1 Italy Oral Antiviral Market by Indication
        • 6.2.4.6.2 Italy Oral Antiviral Market by Drug Class
        • 6.2.4.6.3 Italy Oral Antiviral Market by Distribution Channel
      • 6.2.4.7 Rest of Europe Oral Antiviral Market
        • 6.2.4.7.1 Rest of Europe Oral Antiviral Market by Indication
        • 6.2.4.7.2 Rest of Europe Oral Antiviral Market by Drug Class
        • 6.2.4.7.3 Rest of Europe Oral Antiviral Market by Distribution Channel
  • 6.3 Asia Pacific Oral Antiviral Market
    • 6.3.1 Asia Pacific Oral Antiviral Market by Indication
      • 6.3.1.1 Asia Pacific Human Immunodeficiency Virus (HIV) Market by Country
      • 6.3.1.2 Asia Pacific Hepatitis Market by Country
      • 6.3.1.3 Asia Pacific Influenza Market by Country
      • 6.3.1.4 Asia Pacific Others Market by Country
    • 6.3.2 Asia Pacific Oral Antiviral Market by Drug Class
      • 6.3.2.1 Asia Pacific Reverse Transcriptase Inhibitors Market by Country
      • 6.3.2.2 Asia Pacific Protease Inhibitors Market by Country
      • 6.3.2.3 Asia Pacific Others Market by Country
    • 6.3.3 Asia Pacific Oral Antiviral Market by Distribution Channel
      • 6.3.3.1 Asia Pacific Drug Store & Retail Pharmacies Market by Country
      • 6.3.3.2 Asia Pacific Hospital Pharmacies Market by Country
      • 6.3.3.3 Asia Pacific Online Providers Market by Country
    • 6.3.4 Asia Pacific Oral Antiviral Market by Country
      • 6.3.4.1 China Oral Antiviral Market
        • 6.3.4.1.1 China Oral Antiviral Market by Indication
        • 6.3.4.1.2 China Oral Antiviral Market by Drug Class
        • 6.3.4.1.3 China Oral Antiviral Market by Distribution Channel
      • 6.3.4.2 Japan Oral Antiviral Market
        • 6.3.4.2.1 Japan Oral Antiviral Market by Indication
        • 6.3.4.2.2 Japan Oral Antiviral Market by Drug Class
        • 6.3.4.2.3 Japan Oral Antiviral Market by Distribution Channel
      • 6.3.4.3 India Oral Antiviral Market
        • 6.3.4.3.1 India Oral Antiviral Market by Indication
        • 6.3.4.3.2 India Oral Antiviral Market by Drug Class
        • 6.3.4.3.3 India Oral Antiviral Market by Distribution Channel
      • 6.3.4.4 South Korea Oral Antiviral Market
        • 6.3.4.4.1 South Korea Oral Antiviral Market by Indication
        • 6.3.4.4.2 South Korea Oral Antiviral Market by Drug Class
        • 6.3.4.4.3 South Korea Oral Antiviral Market by Distribution Channel
      • 6.3.4.5 Singapore Oral Antiviral Market
        • 6.3.4.5.1 Singapore Oral Antiviral Market by Indication
        • 6.3.4.5.2 Singapore Oral Antiviral Market by Drug Class
        • 6.3.4.5.3 Singapore Oral Antiviral Market by Distribution Channel
      • 6.3.4.6 Malaysia Oral Antiviral Market
        • 6.3.4.6.1 Malaysia Oral Antiviral Market by Indication
        • 6.3.4.6.2 Malaysia Oral Antiviral Market by Drug Class
        • 6.3.4.6.3 Malaysia Oral Antiviral Market by Distribution Channel
      • 6.3.4.7 Rest of Asia Pacific Oral Antiviral Market
        • 6.3.4.7.1 Rest of Asia Pacific Oral Antiviral Market by Indication
        • 6.3.4.7.2 Rest of Asia Pacific Oral Antiviral Market by Drug Class
        • 6.3.4.7.3 Rest of Asia Pacific Oral Antiviral Market by Distribution Channel
  • 6.4 LAMEA Oral Antiviral Market
    • 6.4.1 LAMEA Oral Antiviral Market by Indication
      • 6.4.1.1 LAMEA Human Immunodeficiency Virus (HIV) Market by Country
      • 6.4.1.2 LAMEA Hepatitis Market by Country
      • 6.4.1.3 LAMEA Influenza Market by Country
      • 6.4.1.4 LAMEA Others Market by Country
    • 6.4.2 LAMEA Oral Antiviral Market by Drug Class
      • 6.4.2.1 LAMEA Reverse Transcriptase Inhibitors Market by Country
      • 6.4.2.2 LAMEA Protease Inhibitors Market by Country
      • 6.4.2.3 LAMEA Others Market by Country
    • 6.4.3 LAMEA Oral Antiviral Market by Distribution Channel
      • 6.4.3.1 LAMEA Drug Store & Retail Pharmacies Market by Country
      • 6.4.3.2 LAMEA Hospital Pharmacies Market by Country
      • 6.4.3.3 LAMEA Online Providers Market by Country
    • 6.4.4 LAMEA Oral Antiviral Market by Country
      • 6.4.4.1 Brazil Oral Antiviral Market
        • 6.4.4.1.1 Brazil Oral Antiviral Market by Indication
        • 6.4.4.1.2 Brazil Oral Antiviral Market by Drug Class
        • 6.4.4.1.3 Brazil Oral Antiviral Market by Distribution Channel
      • 6.4.4.2 Argentina Oral Antiviral Market
        • 6.4.4.2.1 Argentina Oral Antiviral Market by Indication
        • 6.4.4.2.2 Argentina Oral Antiviral Market by Drug Class
        • 6.4.4.2.3 Argentina Oral Antiviral Market by Distribution Channel
      • 6.4.4.3 UAE Oral Antiviral Market
        • 6.4.4.3.1 UAE Oral Antiviral Market by Indication
        • 6.4.4.3.2 UAE Oral Antiviral Market by Drug Class
        • 6.4.4.3.3 UAE Oral Antiviral Market by Distribution Channel
      • 6.4.4.4 Saudi Arabia Oral Antiviral Market
        • 6.4.4.4.1 Saudi Arabia Oral Antiviral Market by Indication
        • 6.4.4.4.2 Saudi Arabia Oral Antiviral Market by Drug Class
        • 6.4.4.4.3 Saudi Arabia Oral Antiviral Market by Distribution Channel
      • 6.4.4.5 South Africa Oral Antiviral Market
        • 6.4.4.5.1 South Africa Oral Antiviral Market by Indication
        • 6.4.4.5.2 South Africa Oral Antiviral Market by Drug Class
        • 6.4.4.5.3 South Africa Oral Antiviral Market by Distribution Channel
      • 6.4.4.6 Nigeria Oral Antiviral Market
        • 6.4.4.6.1 Nigeria Oral Antiviral Market by Indication
        • 6.4.4.6.2 Nigeria Oral Antiviral Market by Drug Class
        • 6.4.4.6.3 Nigeria Oral Antiviral Market by Distribution Channel
      • 6.4.4.7 Rest of LAMEA Oral Antiviral Market
        • 6.4.4.7.1 Rest of LAMEA Oral Antiviral Market by Indication
        • 6.4.4.7.2 Rest of LAMEA Oral Antiviral Market by Drug Class
        • 6.4.4.7.3 Rest of LAMEA Oral Antiviral Market by Distribution Channel

Chapter 7. Company Profiles

  • 7.1 Johnson & Johnson
    • 7.1.1 Company Overview
    • 7.1.2 Financial Analysis
    • 7.1.3 Segmental &Regional Analysis
    • 7.1.4 Research & Development Expenses
    • 7.1.5 SWOT Analysis
  • 7.2 F. Hoffmann-La Roche Ltd.
    • 7.2.1 Company Overview
    • 7.2.2 Financial Analysis
    • 7.2.3 Segmental and Regional Analysis
    • 7.2.4 Research & Development Expense
  • 7.3 Merck & Co., Inc.
    • 7.3.1 Company Overview
    • 7.3.2 Financial Analysis
    • 7.3.3 Segmental and Regional Analysis
    • 7.3.4 Research & Development Expenses
  • 7.4 Bristol Myers Squibb Company
    • 7.4.1 Company Overview
    • 7.4.2 Financial Analysis
    • 7.4.3 Regional Analysis
    • 7.4.4 Research & Development Expenses
  • 7.5 Gilead Sciences, Inc.
    • 7.5.1 Company overview
    • 7.5.2 Financial Analysis
    • 7.5.3 Research & Development Expenses
  • 7.6 Viatris, Inc. (Mylan N.V.)
    • 7.6.1 Company Overview
    • 7.6.2 Financial Analysis
    • 7.6.3 Segmental Analysis
    • 7.6.4 Research & Development Expense
  • 7.7 AbbVie, Inc.
    • 7.7.1 Company Overview
    • 7.7.2 Financial Analysis
    • 7.7.3 Regional Analysis
    • 7.7.4 Research & Development Expense
  • 7.8 GlaxoSmithKline PLC (GSK)
    • 7.8.1 Company Overview
    • 7.8.2 Financial Analysis
    • 7.8.3 Regional Analysis
    • 7.8.4 Research & Development Expense
  • 7.9 Teva Pharmaceutical Industries Ltd.
    • 7.9.1 Company Overview
    • 7.9.2 Financial Analysis
    • 7.9.3 Regional Analysis
    • 7.9.4 Research & Development Expenses
  • 7.10. Amneal Pharmaceuticals, Inc.
    • 7.10.1 Company Overview
    • 7.10.2 Financial Analysis
    • 7.10.3 Segmental Analysis
    • 7.10.4 Research & Development Expenses